Segments
-
Pharmaceutical
-
Consumer Health
-
MedTech
-
Public Health & Government
-
Payer & Provider
Pharmaceutical (Global page)
Bringing data science and human science together to advance human health and support the pharmaceutical industry from clinical trials to commercialization.
Learn More
Consumer Health
Connecting with powerful, evidence-based market insights to drive agile thinking, uncover growth potential, and gain competitive advantage in this fast-moving consumer health market.
LEARN MORE
MedTech
Empowering to orchestrate operations across the entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.
Learn more
Public Health & Government
Working across the health system to address key barriers to deliver high-quality, cost-effective care while improving health outcomes using our data-driven and population-centric solutions.
LEARN MORE
Payer & Provider
Delivering a wide range of consulting and technology solutions to support healthcare stakeholders to drive operational efficiency, enhance quality of patient care, and improve systemic outcomes.
learn moreHealthcare Provider Solutions
Solutions
-
Research & Development
-
Real World Evidence
-
Information Insights
-
Market Research
-
Strategy Consulting
-
Contract Sales & Medical Solutions
-
Patient Solutions
-
AI, Digital & Technology Solutions
Research & Development (Global page)
Clinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.
Learn More
Real World Evidence
Harness the power of real-world data and insights to demonstrate value-driven evidence and outcomes to meet stakeholder needs across the healthcare ecosystem and to propel healthcare forward.
LEARN MORE
Information Insights
Pharmaceutical market data and information assets that provide actionable data points to help organizations make intelligent connections and drive healthcare forward.
LEARN MORE
Market Research
Primary Intelligence integrates purpose-built and syndicated research solutions with our wide range of data assets, research methodologies, advanced analytics, and deep domain expertise, generating quality insights for our clients.
LEARN MORE
Strategy Consulting
Trusted advisor and partner to global healthcare organisations, solving the most significant business challenges through extensive healthcare expertise.
LEARN MORERelated Solutions
Contract Sales & Medical Solutions (Global page)
Optimize commercial success by leveraging our comprehensive outsourced expertise to accelerate time-to-market.
LEARN MORE
Patient Solutions (Global page)
A single window solution provider to support pharmaco’s design, deploy technology and services that help increase access to medicine and improve treatment adherence.
LEARN MORE
AI, Digital & Technology Solutions
Connected Intelligence™, digital insights, data analytics and advanced technology to power smarter decision-making to enable better patient outcomes and improved business results.
LEARN MOREOur Latest Whitepapers
Get the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific.
Learn MoreBlogs, Case Studies & Podcasts
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
Discover Insights
Our Latest White Paper
"Unlocking Pharmaceutical Potential: The Growing Role of Thai Clinics
Read more
Career Opportunities
Improving human health needs innovative thinkers. Unleash your potential with us.
Search JobsIndustry Analyst Reports
Discover how industry experts recognize IQVIA's impact across the Asia Pacific region.
LEARN MORE
Livre Blanc
Radioligand Therapy as the Future of Cancer Care in Singapore
Aug 27, 2025
Prostate cancer is the most common cancer among men in Singapore, with a considerable proportion of cases expected to progress to advanced stages, including PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), which is projected to affect up to 850 patients by 2040. However, current standard treatments such as androgen receptor pathway inhibitors (ARPIs) and chemotherapy leave persistent care gaps including delayed diagnoses, limited referrals and poor treatment tolerance which risk compromising patient outcomes.
In this white paper, we explore how Radioligand Therapy (RLT), particularly Lutetium-177 (Lu-177) PSMA-targeted treatment, could be pivotal in closing these gaps, improving progression-free survival and quality of life, and strengthening Singapore's cancer care system through advances in PSMA-PET imaging, nuclear medicine infrastructure, specialist workforce, regulatory frameworks, and funding support.
Authors:
- Smitha Sreedharan, Associate Director, Medical Writing, IQVIA
- Steven Surja, Consultant, Strategy Consulting, IQVIA
- Adivitiya Bihagara, Medical Writer 2, RWE Medical and Scientific Writing, IQVIA